.jpg "Emma L. Harvey, BSc, MBBS, MRCP, FFPM photo")
Global Head of Medical Affairs
F2G Ltd, United Kingdom
Dr Emma Harvey, BSc, MBBS, MRCP, FFPM
Global Head of Medical Affairs, F2G, Ltd.
Emma is a pharmaceutical physician of over 20 years standing with experience in developing and launching new products as well as lifecycle management. She has been at F2G for 5 years and holds an FDA grant for the development of a patient reported outcomes instrument to assess the impact of living with coccidioidomycosis on patients’ lives. She has established, in collaboration with Paul Verweij and Tom Chiller, an industry/academia/government steering committee to investigate potential threats to human health posed by novel agricultural fungicides which share the same mechanism of action as human antifungals, particularly those in clinical development. She worked in rare diseases at Alexion Pharmaceuticals, as UK Medical Director. Prior to this she spent nearly seven years at Gilead Sciences as International Medical Director for AmBisome®, during which time she led the lifecycle Project Team, overseeing the initiation of a major phase IV clinical trial, working with academics to support the phase 2 study of liposomal amphotericin B in cryptococcal meningitis and creating the CARE (Continuing Antifungal and Research Education programme.) She is a Member of the Royal College of Physicians (London) and a Fellow of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians and sits on the Board of Trustees.